Turning science into business: An optimised alternative to antibodies
Drug Discovery World
APRIL 3, 2023
I quickly recognised the commercial value of aptamers as being able to address the gap in the market where antibodies fail to perform, and together we established the business to begin aptamer development. DS: The company now has clients across big pharma. To what do you attribute your success?
52 
Let's personalize your content